As the rise of molecular imaging technology is unlocking the potential of precision medicine, DPM, an emerging player in the field, focuses on the development of intraoperative precision optical molecular imaging technologies and products.
DPM(Chinese: 迪谱医疗), short for Digital Precision Medicine, announced its completion of Series B round worth hundreds of millions of CNY, led by S.B. China Capital and Longmen Investment(Chinese:中关村龙门投资) with participation from Icommon Capital(Chinese: 江苏皓越基金) and Risheng Fund(Chinese: 杭州日昇基金). The proceeds will be used to accelerate innovation, marketing and team building.
DPM, whose founder is Dr. Jie Tian, a professor at Chinese Academy of Sciences(short for CAS), was incubated in the Laboratory of Molecular Imaging of CAS.
Dr. Tian said DPM's business covers theoretical research, technology development, clinical translation and industrial promotion. The company has developed and produced the 4K fluorescence endoscopy camera system, medical endoscopy cold light source, near-infrared fluorescence imaging system, fluorescence molecular imager and white light endoscopy camera system. DPM planned to develop a full range of molecular imaging equipment and consumables, aiming to be the leader in molecular imaging.
With three series of high-end optical molecular imaging surgical navigation devices and multiple white light endoscopy camera system products, the company is also improving its product lines, such as the 3D endoscope, 3D fluorescence endoscope and broad-spectrum AI endoscope.
Up until now, 13 products of DPM have obtained the NMPA registration certificate and the CE certification.
Preliminary research of DPM was supported by multiple key projects funded by the Chinese government. The company also led a project called ‘R&D of Digital Diagnostic Equipment’ supported by China’s Science and Technology Ministry and made a breakthrough in intraoperative precision imaging of liver cancer. DPM has more than 100 intellectual property rights, including U.S. patents.
In the future, DPM will advance from precision surgery to precision health, relying on the new magnetic nanoparticle detection and imaging technology.
The competitors of DPM include Kangji Medical(Chinese: 康基医疗), Tuge Medical(Chinese: 图格医疗), Endo View(Chinese: 欧太医疗).